Lipid-Based Gliclazide Nanoparticles for Treatment of Diabetes: Formulation, Pharmacokinetics, Pharmacodynamics and Subacute Toxicity Study
Alaa Mohamed Nazief,1 Passainte Saber Hassaan,2 Hoda Mahmoud Khalifa,3 Magda Samir Sokar,1 Amal Hassan El-Kamel1 1Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt; 2Department of Medical Physiology, Faculty of Medicine, Alexandria University, Alexandria, Egy...
Guardado en:
Autores principales: | Nazief AM, Hassaan PS, Khalifa HM, Sokar MS, El-Kamel AH |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a974907dc9af4c449c327a4787f1b036 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
SIMULTANEOUS DETERMINATION OF ROSIGLITAZONE AND GLICLAZIDE IN PHARMACEUTICAL DOSAGE FORMS BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
por: LAKSHMI,K.S, et al.
Publicado: (2010) -
Low risk of hypoglycemia and high efficacy of gliclazide MB: results of recent studies
por: I. V. Kononenko, et al.
Publicado: (2021) -
Current data on the effectiveness of gliclazide and molecular mechanisms of action of the drug
por: Nina A. Petunina, et al.
Publicado: (2020) -
Pharmacoscintigraphic evaluation and antidiabetic efficacy of gliclazide-loaded 99mTc-labelled mucoadhesive microspheres
por: Ripunjoy Bordoloi, et al.
Publicado: (2021) -
Pharmacokinetics and Biodistribution of Thymoquinone-loaded Nanostructured Lipid Carrier After Oral and Intravenous Administration into Rats
por: Zakarial Ansar FH, et al.
Publicado: (2020)